We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

100 hedge funds and large institutions have $739M invested in Avidity Biosciences in 2021 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 43 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

258% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 12

225% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 8

22% more funds holding

Funds holding: 82 → 100 (+18)

7.65% more ownership

Funds ownership: 82.5% → 90.15% (+7.7%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6% less capital invested

Capital invested by funds: $790M → $739M (-$51.3M)

Holders
100
Holders Change
+18
Holders Change %
+21.95%
% of All Funds
1.76%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
26
Increased
43
Reduced
12
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$19.9M
2
State Street
State Street
Massachusetts
+$16.3M
3
BlackRock
BlackRock
New York
+$16.2M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$11.5M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$9.03M

Top Sellers

1
LGM
Logos Global Management
California
-$17.1M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$5.52M
3
ACM
Alethea Capital Management
Washington
-$4.54M
4
TG
TCW Group
California
-$4.13M
5
ACP
Acuta Capital Partners
California
-$4.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$87.1M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$74.9M +$231K +9,453 +0.3%
BlackRock
3
BlackRock
New York
$58.7M +$16.2M +660,470 +33%
CAM
4
Cormorant Asset Management
Massachusetts
$53.8M -$49 -2 -0%
EC
5
EcoR1 Capital
California
$45.9M – – –
Federated Hermes
6
Federated Hermes
Pennsylvania
$39.3M +$9.03M +368,834 +26%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$38.3M +$19.9M +812,897 +86%
ACM
8
Alethea Capital Management
Washington
$30.2M -$4.54M -185,296 -12%
State Street
9
State Street
Massachusetts
$29.4M +$16.3M +667,679 +98%
Vanguard Group
10
Vanguard Group
Pennsylvania
$28M +$11.5M +468,745 +58%
MCMC
11
Matrix Capital Management Company
New Hampshire
$26.2M – – –
BC
12
Boxer Capital
California
$24.5M – – –
PA
13
Perceptive Advisors
New York
$24M -$3.35M -136,790 -11%
Victory Capital Management
14
Victory Capital Management
Texas
$22.3M +$4.13M +168,764 +20%
Alkeon Capital Management
15
Alkeon Capital Management
New York
$19.1M – – –
ACA
16
Avoro Capital Advisors
New York
$11.9M – – –
DM
17
Deerfield Management
New York
$9.9M – – –
OCA
18
Octagon Capital Advisors
New York
$9.74M +$406K +16,600 +4%
HA
19
HHLR Advisors
Cayman Islands
$9.27M – – –
AWA
20
Aaron Wealth Advisors
Illinois
$8.95M -$2.79M -114,058 -22%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$8.85M +$3.43M +140,086 +53%
Goldman Sachs
22
Goldman Sachs
New York
$7.96M +$3.45M +140,901 +63%
Deutsche Bank
23
Deutsche Bank
Germany
$7.45M +$5.62M +229,472 +204%
Wellington Management Group
24
Wellington Management Group
Massachusetts
$6.89M -$5.52M -225,404 -42%
Northern Trust
25
Northern Trust
Illinois
$6.27M +$2.34M +95,456 +50%
1
2 3 4 5

RNAM Hedge Fund Activity: Q1 2021 in Review

100 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q1 2021, worth a combined $739M — down 6.5% from $790M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new RNAM positions and 8 closed out — a net gain of 18 holders — while 43 added to existing stakes and 12 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $19.9M. The largest seller was Logos Global Management, exiting entirely with an estimated $17.1M sold.

  • 100 institutional investors held Avidity Biosciences (RNAM) as of Q1 2021, up from 82 in Q4 2020.
  • Funds reported $739M of Avidity Biosciences stock for Q1 2021, down 6.5% quarter-over-quarter.
  • 26 funds opened new Avidity Biosciences positions in Q1 2021 and 8 closed out, a net change of +18 holders.
  • The largest Avidity Biosciences buyer in Q1 2021 was T. Rowe Price Associates, an estimated $19.9M added.
  • The largest Avidity Biosciences seller in Q1 2021 was Logos Global Management, an estimated $17.1M sold.

Based on aggregated 13F filings for Q1 2021.